The US Food and Drug Administration (FDA) has approved scPharmaceuticals’ supplemental new drug application (sNDA) for ...

Pharmaceuticals (SCPH) announced that the FDA has approved the supplemental new drug application for Furoscix to expand the indication to ...

The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...

Analysts expect scPharmaceuticals to post earnings of ($0.39) per share and revenue of $12.08 million for the quarter. scPharmaceuticals Price Performance Shares of NASDAQ:SCPH opened at $2.93 on ...

TD Cowen analyst Stacy Ku maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) today and set a price target of $25.00.Discover ...

But that doesn't mean long term investors can avoid big losses. To wit, the scPharmaceuticals Inc. (NASDAQ:SCPH) share price managed to fall 68% over five long years. That is extremely sub-optimal ...

Rhumbline Advisers’ holdings in scPharmaceuticals were worth $151,000 at the end of the most recent quarter. Several other hedge funds have also made changes to their positions in SCPH.

Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization FDA approves scPharmaceuticals' expanded Furoscix indication ...